- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-Hodgkin’s lymphoma (NHL); Chronic lymphocytic leukaemia (CLL); Rheumatoid arthritis (RA); Granulomatosis with polyangiitis (Wegener’s granulomatosis) (GPA); Microscopic polyangiitis (MPA).
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 367KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 52KB)
Rituximab – November 2021
Rituximab: Solution for I.V. infusion 100 mg in 10 mL, Solution for I.V. infusion 500 mg in 50 mL; Ruxience®
Last updated
4 March 2022